Risk stratification and medical therapy of pulmonary arterial hypertension
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 Time-course of completed randomised controlled trials (RCTs) in pulmonary arterial hypertension (PAH) (n=41) according to treatment strategy. SSc: systemic sclerosis; IPAH: idiopathic PAH. Reproduced and modified from [70] with permission.](https://figures.cochat.ai/paper-figures/44281cb9913845f29b53a42c8e3258e5/risk-stratification-and-medical-therapy-of-pulmonary-arterial-hypertension-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other high-risk profiles include familial PAH, PVOD, CTD-PAH, CTD-PAH associated with concomitant ILD, rapidly progressive disease despite therapy, and development of hemoptysis.(282, 291–293)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, the 2018 World Symposium on Pulmonary Hypertension strongly recommends serial parametric risk assessment.(282)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
The cited source says what the claim attributes to it.
In the citing paper
“The 2018 World Symposium on Pulmonary Hypertension states that the ultimate goal of therapy for patients with PAH is to achieve a low-risk status, assessed either by REVEAL or the ESC/ERS model.(282)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationBenza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Self-citationChannick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,534
Self-citation
Research works printed but not linked: 2
- Benza, 2018, Comparison of three assessment strategies as predictors of one-year survival in US pulmonary arterial hypertension (PAH) patients, Am J Respir Crit Care Med, 197, A7649
- Galiè, 2014, AMBITION: a randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH), Eur Respir J, 44, 2916
Cited by
Items 601–700 of 897
Chiansirikraivuti, N., Sapankaew, T., & Pirompanich, P. (2022) · Lung India · doi:10.4103/lungindia.lungindia_453_22 · Cited by 2
Chen, J., Huayu, M., Su, S., Wang, S., Yang, Z., Nan, X., Lu, D., & Li, Z. (2023) · Natural Product Communications · doi:10.1177/1934578x221148896 · Cited by 2
Bobhate, P., Gupta, R. K., Karande, T., & Kulkarni, S. M. (2023) · The National Medical Journal of India · doi:10.25259/nmji_35_6_338 · Cited by 2
Pregnancy Management in Patients with Pulmonary Arterial Hypertension
Low, T. T., & Silversides, C. K. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-34103-8_23 · Cited by 2
Davis, S., Edwards, T., Norcross, L., Fehnel, S. E., Beaudet, A., Eckart, M., & Fastenau, J. M. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00673-w · Cited by 2
CURRENT ASPECTS OF THE MANAGEMENT OF PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
Khidirova, L. D., & Tyupina, V. N. (2024) · Vrach · doi:10.29296/25877305-2024-09-08 · Cited by 2
Schneider, S., Lichtblau, M., Müller, J., Bauer, M., Mayer, L., Schwarz, E. I., Furian, M., Saxer, S., & Ulrich, S. (2025) · ERJ Open Research · doi:10.1183/23120541.01392-2024 · Cited by 2
Dai, J., Ma, L., Zhang, Y., Shan, L., Li, D., Li, L., Hu, Q., Zhou, Z., Sun, X., Wang, Q., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04691-y · Cited by 2
Furtado, A. F. P., da Silva, S. L., da Silva, A. X., Silva, M. D. S., dos Santos, A. H. S., dos Santos, P. H. A., Carneiro, M. A. P. A., & Silva, A. C. B. D. M. (2025) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e20645.2025 · Cited by 2
Tadalafil for Treatment of Pulmonary Hypertension: Mechanisms, Evidence, and Emerging Perspectives
Elattar, S., Basha, N. R., Salem, A. M., Abdulfattah, A., Taha, S., Frishman, W. H., Aronow, W. S., & Lanier, G. M. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001036 · Cited by 2
Novel Therapeutic Approaches of Pulmonary Arterial Hypertension
Tyagi, S., & Batra, V. (2019) · International Journal of Angiology · doi:10.1055/s-0039-1692140 · Cited by 2
Updates in pulmonary hypertension and other pulmonary vascular diseases
Bernardo, R. J., Bokan, A., & Ramjug, S. (2019) · Breathe · doi:10.1183/20734735.0187-2019 · Cited by 2
Long-term experience with implantable treprostinil pumps in pulmonary arterial hypertension
Dytrych, V., Kuchař, J., Ambrož, D., Kunstýř, J., Grus, T., Lindner, J., Linhart, A., & Jansa, P. (2020) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2020_057 · Cited by 2
Kopp, G., Hachulla, A.-L., Noble, S., Bringard, A., Soccal, P. M., Beghetti, M., & Lador, F. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.539707 · Cited by 2
Abdi, S. A., Almoushref, A., Naal, T., Melillo, C. A., Aulak, K. S., Ahmed, M., Chatterjee, S., Highland, K. B., Dweik, R. A., & Tonelli, A. R. (2021) · Microcirculation · doi:10.1111/micc.12734 · Cited by 2
Shi, Q., Wang, Z., Yang, N., Ma, Y., Chen, Y., Wei, H., & Yao, H. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-21-3979 · Cited by 2
Luque, M. C. A., Vega, J. D. S., Salinas, G. L. A., & Gómez, J. L. Z. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.06.003 · Cited by 2
A Health State Utility Study to Elicit Societal Values Associated with Pulmonary Hypertension
Nafees, B., de Freitas, H. M., Beaudet, A., Todd, E., & Gin‐Sing, W. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s400061 · Cited by 2
Foster, E. M., Sullinger, D., & Coons, J. C. (2023) · Pharmacy · doi:10.3390/pharmacy11050145 · Cited by 2
Richter, M. J., & Tello, K. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-2069ed · Cited by 2
Channick, R. N., & Saggar, R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.07.004 · Cited by 2
Self-citationBeshay, S. M., & Sahay, S. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.11.010 · Cited by 2
Time Is of the Essence in PAH Therapy
Naranjo, M., & Hassoun, P. M. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.02.009 · Cited by 2
Initial Triple Pharmacotherapy in Pulmonary Arterial Hypertension
Leopold, J. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.007 · Cited by 2
Jin, Q., Guan, L., Pan, W., & Zhou, D. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202107-1622le · Cited by 2
Ampnti, S. A., Almoushref, A., Naal, T., Melillo, C. A., Aulak, K. S., Ahmed, M., Chatterjee, S., Highland, K. B., Dweik, R. A., & Tonelli, A. R. (2021) · Research Square · doi:10.21203/rs.3.rs-144093/v1 · Cited by 2
To be or not to be… treated with initial combination therapy, that is the (PAH) question
Boucly, A., Humbert, M. J. C., & Sitbon, O. (2022) · European Respiratory Journal · doi:10.1183/13993003.00390-2022 · Cited by 2
Risk Assessment Tools in Pulmonary Arterial Hypertension
Ruopp, N. F., & Farber, H. W. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.06.3819 · Cited by 2
Update pulmonale Hypertonie mit Fokus auf Lungenkrankheiten
Foris, V., Kovács, G., & Olschewski, H. (2021) · Der Pneumologe · doi:10.1007/s10405-021-00392-3 · Cited by 1
Rayroux, C., Lador, F., Soccal, P. M., Plojoux, J., & Adler, D. (2022) · JMIG · doi:10.53738/revmed.2022.18.764-65.64 · Cited by 1
A clinician's guide to pulmonary hypertension
Wilson, B. K., Sadowski, C. K., & Baeten, R. G. (2024) · JAAPA · doi:10.1097/01.jaa.0001007360.09090.5f · Cited by 1
Zhai, Y., Li, A., Tao, X., Gao, Q., Xie, W., Zhang, Y., Chen, A., Wang, C., Lei, J., Ding, S., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04053-0 · Cited by 1
Huang, W.-C., Cheng, Y., Hsu, C., Wu, Y.-J., Cheng, C., Ho, W.-J., Chuang, H., Chu, C., Lin, K., Wang, L.-Y., et al. (2024) · PubMed Central · doi:10.6515/acs.202411_40(6).20240729a · Cited by 1
Hu, B., Zhong, H., Shi, R., Chen, Z., Liu, A., Li, X., Zhou, D., Lai, J., Zhang, C., Chen, Y., et al. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.107884 · Cited by 1
Murta, M. S., Duarte, R., Waetge, D., Gozal, D., Cardoso, A. P., & Mello, F. C. D. Q. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.04.021 · Cited by 1
Ranjan, N., Ahmed, A., Jordana, W., Selvaraj, R., Mihir, P., Dalati, Y., Sabanathan, V., & Thanujan, T. (2025) · Journal of Pulmonology and Respiratory Research · doi:10.29328/journal.jprr.1001068 · Cited by 1
Revolutionizing Clinical Trials in Systemic Sclerosis
Nuaaman, M. M., & Pope, J. E. (2025) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-025-00236-8 · Cited by 1
Kiyota, T. A., Mendes, P., & Pereira, M. C. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2601388 · Cited by 1
Plunkett, M. J., Sayegh, A. L. C., Lewis, R. A., McWilliams, T. J., Sithamparanathan, S., Paton, J. F. R., & Fisher, J. P. (2026) · Respirology · doi:10.1002/resp.70207 · Cited by 1
Vanni, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms272210221 · Cited by 1
Marqués, R. B., Rivas-Ruiz, F., Tenes, A., Becerra, V., Ortiz, E., de Miguel, I. M., Barberà, J. A., López‐Meseguer, M., Capote, P. A. C., Vich, I. B., et al. (2026) · Rheumatology · doi:10.1093/rheumatology/keag105 · Cited by 1
Zhao, D., Li, Y., Yang, Y., Yu, F., Heidari, A. A., Chen, Y., Chen, H., & Wu, P. (2026) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2026.2634406 · Cited by 1
Kholdani, C. A., Paoli, C. J., Peck, T. J., Tang, W., Schoenberg, N. C., Panjabi, S. S., & Furfaro, D. M. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70255 · Cited by 1
Dandel, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062368 · Cited by 1
Zhang, J. (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102345 · Cited by 1
Ye, M., Yan, P., Guan, X., Li, M., Guan, Y., Li, H., Tang, Y., Liu, W., & Deng, D. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/6652927 · Cited by 1
Alqarni, A. A., Aljedani, R. H., Aldhahir, A. M., Alasimi, A. H., Al-Garni, A., Alqahtani, J. S., Alghamdi, S. M., Siraj, R. A., Mengash, A. S., & Alwafi, H. H. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70337 · Cited by 1
Hansmann, G., Idorn, L., Melicoff, E., Justino, H., Anjos, R. T., Bates, A., Bobylev, D., Budts, W., Diekmann, F., Hasan, B. S., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.01.013 · Cited by 1
Differenzialdiagnose ist bei pulmonaler Hypertonie therapieentscheidend
Rosenkranz, S. (2019) · Pneumo News · doi:10.1007/s15033-019-1154-5 · Cited by 1
Boucly, A. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30046-1 · Cited by 1
Simakova, M. A., & Моисеева, О. М. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-04-13 · Cited by 1
Hjalmarsson, C., Butler, O., Hesselstrand, R., Holl, K., Jansson, K., Klok, R. M., Rådegran, G., Söderberg, S., & Kjellström, B. (2020) · Pulmonary Circulation · doi:10.1177/2045894020958557 · Cited by 1
Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension
Huston, J., & Hemnes, A. R. (2020) · Respiratory medicine · doi:10.1007/978-3-030-52787-7_10 · Cited by 1
Leuchte, H. H., Halank, M., Held, M., Borst, M. M., Ewert, R., Klose, H. F. E., Lange, T. J., Meyer, F. J., Skowasch, D., Wilkens, H., et al. (2021) · Pneumologie · doi:10.1055/a-1204-3248 · Cited by 1
Pulmonary Hypertension: A Simplified Pulmonologists' Perspective
Utpat, K. V., Desai, U. D., Doshi, K., & Joshi, J. M. (2021) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_48_20 · Cited by 1
Systemic sclerosis and pulmonary hypertension
Özmen, M., Gücenmez, S., & Otman, E. (2021) · Ulusal Romatoloji Dergisi · doi:10.4274/raed.galenos.2021.50570 · Cited by 1
Palliative Care in Pulmonary Arterial Hypertension
Christiansen, D. L., Weatherald, J. C., & Orlikow, E. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_14 · Cited by 1
Proshkina, A., Tsareva, N. A., Nekludova, G. V., & Avdeev, S. N. (2021) · Kardiologiia · doi:10.18087/cardio.2021.10.n1789 · Cited by 1
El‐Kersh, K. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001526 · Cited by 1
Gaps of evidence in pulmonary arterial hypertension
Vizza, C. D., Ghio, S., Badagliacca, R., Manzi, G., Scelsi, L., Argiento, P., & D’Alto, M. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.026 · Cited by 1
Hipertensión pulmonar en cardiopatías congénitas del adulto
(2022) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.37.1.7 · Cited by 1
Expert provider survey of longitudinal assessment in patients with pulmonary arterial hypertension
Kingrey, J. F., Zhou, C. Y., Dalal, B., & Elwing, J. (2022) · Heart & Lung · doi:10.1016/j.hrtlng.2022.10.016 · Cited by 1
Protocolo terapéutico de la hipertensión pulmonar sin cardiopatía izquierda
Pintado, B., & Tenes, A. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.11.014 · Cited by 1
Transplantation pulmonaire pour hypertension pulmonaire sévère
Pavec, J. L., Savale, L., Prévôt, G., Montani, D., Sitbon, O., Fadel, É., Humbert, M. J. C., & Mercier, O. M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.010 · Cited by 1
Antagonistas de los receptores de la endotelina
Mayoral, A. R. (2023) · Spanish Journal of Medicine · doi:10.24875/sjmed.m22000012 · Cited by 1
Farina, S., Pezzuto, B., Vignati, C., Laveneziana, P., & Agostoni, P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1241379 · Cited by 1
Exercise Rehabilitation is Underutilized Among Veterans With Pulmonary Hypertension
CASCINO, T. M., Schopfer, D. W., Meyer, C. S., Zhang, N., Barnes, G. D., McLaughlin, V. V., Jackson, E. A., & Whooley, M. A. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.08.095 · Cited by 1
Self-citationHypertension pulmonaire : comment différencier les causes fréquentes et rares?
Genecand, L., Firmann, M., Gijs, P.-J., Lechartier, B., & Lador, F. (2023) · JMIG · doi:10.53738/revmed.2023.19.850.2138 · Cited by 1
Umetani, K., & Atsumi, M. (2023) · BMJ Case Reports · doi:10.1136/bcr-2023-255810 · Cited by 1
Ivanov, S. N., Edemskiy, A. G., Agarkova, M. A., Содномова, Л. Б., Гармаева, О. В., & Balzhinov, D. B. (2024) · Современные проблемы науки и образования · doi:10.17513/spno.33252 · Cited by 1
A novel interaction between aquaporin 1 and caspase-3 in pulmonary arterial smooth muscle cells
Niedermeyer, S. E., Yun, X., Trujillo, M., Jiang, H., Andrade, M. R., Kolb, T. M., Suresh, K. S., Damarla, M., & Shimoda, L. A. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00017.2024 · Cited by 1
Dai, Z., Chen, Y., Hsieh, S., Yeh, J., Hsu, J., & Wu, B. (2024) · Pharmaceuticals · doi:10.3390/ph17040440 · Cited by 1
Sun, L., Zhao, X., Hou, X., Zhang, Y., Quan, T., Dong, L., Rao, G., Ren, X., Liang, R., Nie, J., et al. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.06.016 · Cited by 1
Vessels and pressures: Update on the management of pulmonary arterial hypertension
Klinger, J. R. (2024) · Journal of Precision Respiratory Medicine · doi:10.2500/jprm.2023.7.240001 · Cited by 1
Efficacy and Safety of Sotatercept in Pulmonary Arterial Hypertension: A Systematic Review
Afra, L. G., Mousavi, A., Mirzaei, M., Rahimi, Y., Khosravi, F., & Rahmanian, M. (2024) · International Cardivascular Research Journal · doi:10.5812/icrj-151870 · Cited by 1
Meta-analysis evaluating the risks and outcomes of pulmonary hypertension in pregnant women
Li, Y., Yang, X., Zeng, M., Luo, T., Lian, X., Liu, J., Liu, Q., & Xiao, F. (2025) · Pregnancy Hypertension · doi:10.1016/j.preghy.2025.101241 · Cited by 1
Editorial commentary: Challenges in the diagnosis and management of pulmonary artery stenosis
Cirulis, M. M., & Lahm, T. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.02.004 · Cited by 1
Hit Early and Hit Hard in Pulmonary Arterial Hypertension? Not So Fast!
Hassoun, P. M., & Farber, H. W. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202107-1570ed · Cited by 1
Florio, G., Imber, D. A., & Berra, L. M. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2706le · Cited by 1
Weatherald, J. C., & Humbert, M. J. C. (2019) · European Respiratory Society eBooks · doi:10.1183/9781849840798.011818 · Cited by 1
Pulmonary Arterial Hypertension Management in Asia
Fung, E. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.04.002 · Cited by 1
Progesterone is an Inducement of Heritable Pulmonary Arterial Hypertension with BMPR2 MutationPreprint
Hu, W., Zhang, S.-J., Ding, Y., Fang, J., Zhou, L., Xie, S., Ge, X., Fu, L., Li, Q. Y., Qu, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.21.537897 · Cited by 1
Condliffe, R. A., Dorfmüller, P., Gopalan, D., Sitbon, O., & Noordegraaf, A. V. (2023) · European Respiratory Review · doi:10.1183/16000617.0237-2023 · Cited by 1
Entwicklung von pulmonalarteriellem Blutdruck bei terminalen Lungenerkrankungen
Grauvogl, N. A. (2023) · doi:10.5282/edoc.32830 · Cited by 1
Pulmonary Hypertension in Older Patients
Smith, K. A., & Waxman, A. B. (2011) · Respiratory medicine · doi:10.1007/978-1-60761-727-3_6
Weatherald, J. C., Mai, V., & Provencher, S. (2020) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2020.1725791
Malaspinas, I. (2019) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:123504
Pulmonale Hypertonie: Update 2019
Rosenkranz, S. (2019) · Der Klinikarzt · doi:10.1055/a-1014-6954
Current Clinical Management and Basic Research in Pediatric Pulmonary Hypertension
Nagai, A. (2019) · Japanese Society of Pediatric Cardiology and Cardiac Surgery · doi:10.9794/jspccs.35.136
Risk Stratification—What's My Risk? A Practitioner's Tool
Preston, I. R. (2019) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-18.3.84
Self-citationRebuttal From Drs Humbert and Lau
Humbert, M. J. C., & Lau, E. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.07.003
Rebuttal From Drs Channick and Saggar
Channick, R. N., & Saggar, R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.07.006
Self-citationHow the Right Heart Is Measuring Up in Pulmonary Hypertension
Gaine, S. (2020) · CHEST Journal · doi:10.1016/j.chest.2019.09.038
The evolution of the European Respiratory Journal : ready for the new decade!
Chalmers, J. D., Reeves, E. L., Bullen, N. J., & Kolb, M. R. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.02503-2019
Group 1 Clinical Features and Treatment
Ruopp, N. F., & Waxman, A. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11504-1
Selexipag Use in Clinical Practice
White, R. J., & Lachant, D. J. (2020) · CHEST Journal · doi:10.1016/j.chest.2019.12.015
The significance of risk stratification in pulmonary arterial hypertension
Jansa, P. (2019) · Intervenční a akutní kardiologie · doi:10.36290/kar.2019.048
Ricardo Fritz, G., Felipe Aller, R., Joel Melo, T., Francisco Arancibia, H., & Mónica Zagolín, B. (2020) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482020000100041
ЛЕГОЧНАЯ ГИПЕРТЕНЗИЯ: ОТ ABEL AYERZA ДО НАШИХ ДНЕЙ (ОБЗОР ЛИТЕРАТУРЫ)
Поляков, К. В. (2019) · Университетская клиника · doi:10.26435/uc.v0i1(30).298
Zelt, J. G. E. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24965
Metadata
- Authors
- Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., & McLaughlin, V. V.
- Affiliations
- University of Bologna (IT)
- Harvard University (US)
- Mayo Clinic (US)
- University Hospital Heidelberg (DE)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tufts University (US)
- Houston Methodist (US)
- International University of Health and Welfare (JP)
- University of Michigan (US)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801889
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351343
- OpenAlex
- W2904385559
- Cited by
- 819
- References
- 88
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 101 · 2023: 108 · 2022: 174 · 2021: 169 · 2020: 128 · 2019: 58
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Funders
- Japan Society for the Promotion of Science (18K08183)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, risk stratification, medical therapy, combination therapy, treatment escalation, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues, right ventricular function, exercise capacity, one-year mortality, lung transplantation, treatment algorithm
- MeSH terms
- Pulmonary Arterial Hypertension, Calcium Channel Blockers, Humans, Randomized Controlled Trials as Topic, Lung Transplantation, Practice Guidelines as Topic, Risk Assessment, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.